Cargando…

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

INTRODUCTION: 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes. OBJECTIVES: In preparation for a study in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckweg, J., Mason, N., Van Leeuwen, C., Tönnes, S., Terwey, T., Ramaekers, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567880/
http://dx.doi.org/10.1192/j.eurpsy.2022.1846
_version_ 1784809509980471296
author Reckweg, J.
Mason, N.
Van Leeuwen, C.
Tönnes, S.
Terwey, T.
Ramaekers, J.
author_facet Reckweg, J.
Mason, N.
Van Leeuwen, C.
Tönnes, S.
Terwey, T.
Ramaekers, J.
author_sort Reckweg, J.
collection PubMed
description INTRODUCTION: 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes. OBJECTIVES: In preparation for a study in patients with depression, the present study GH001-HV-101 aimed to assess the impact of four different dose levels of a novel vaporized 5-MeO-DMT formulation (GH001) administered via inhalation as single doses, and in an individualized dose escalation regimen on the safety, tolerability, and the dose-related psychoactive effects in healthy volunteers (n=22). Further, we aimed to assess the impact on cognitive functioning, mood, and well-being. METHODS: The psychedelic experience was assessed with a novel Peak Experience Scale (PES), the Mystical Experience Questionnaire (MEQ), the Ego Dissolution Inventory (EDI), the Challenging Experience Questionnaire (CEQ), and the 5-Dimensional Altered States of Consciousness Questionnaire (5D-ASC). RESULTS: 5-MeO-DMT produced dose-related increments in the intensity of the psychedelic experience ratings on all questionnaires, except the CEQ. Prominent effects were observed following single doses of 6, 12, and 18 mg on PES and MEQ ratings, while maximal effects on PES, MEQ, EDI, and 5D-ASC ratings were observed following individualized dose escalation of 5-MeO-DMT. Measures of cognition, mood, and well-being were not affected. Vital signs at 1 and 3 h after administration were not affected and adverse events were generally mild and resolved spontaneously. CONCLUSIONS: Individualized dose escalation of 5-MeO-DMT may be preferable over single dose administration for clinical applications that aim to enhance the short-term psychoactive effects to elicit a strong therapeutic response. DISCLOSURE: This study was funded by GH Research PLC, Dublin, Ireland.
format Online
Article
Text
id pubmed-9567880
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95678802022-10-17 A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers Reckweg, J. Mason, N. Van Leeuwen, C. Tönnes, S. Terwey, T. Ramaekers, J. Eur Psychiatry Abstract INTRODUCTION: 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes. OBJECTIVES: In preparation for a study in patients with depression, the present study GH001-HV-101 aimed to assess the impact of four different dose levels of a novel vaporized 5-MeO-DMT formulation (GH001) administered via inhalation as single doses, and in an individualized dose escalation regimen on the safety, tolerability, and the dose-related psychoactive effects in healthy volunteers (n=22). Further, we aimed to assess the impact on cognitive functioning, mood, and well-being. METHODS: The psychedelic experience was assessed with a novel Peak Experience Scale (PES), the Mystical Experience Questionnaire (MEQ), the Ego Dissolution Inventory (EDI), the Challenging Experience Questionnaire (CEQ), and the 5-Dimensional Altered States of Consciousness Questionnaire (5D-ASC). RESULTS: 5-MeO-DMT produced dose-related increments in the intensity of the psychedelic experience ratings on all questionnaires, except the CEQ. Prominent effects were observed following single doses of 6, 12, and 18 mg on PES and MEQ ratings, while maximal effects on PES, MEQ, EDI, and 5D-ASC ratings were observed following individualized dose escalation of 5-MeO-DMT. Measures of cognition, mood, and well-being were not affected. Vital signs at 1 and 3 h after administration were not affected and adverse events were generally mild and resolved spontaneously. CONCLUSIONS: Individualized dose escalation of 5-MeO-DMT may be preferable over single dose administration for clinical applications that aim to enhance the short-term psychoactive effects to elicit a strong therapeutic response. DISCLOSURE: This study was funded by GH Research PLC, Dublin, Ireland. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567880/ http://dx.doi.org/10.1192/j.eurpsy.2022.1846 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Reckweg, J.
Mason, N.
Van Leeuwen, C.
Tönnes, S.
Terwey, T.
Ramaekers, J.
A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
title A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
title_full A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
title_fullStr A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
title_full_unstemmed A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
title_short A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
title_sort phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-n,n-dimethyltryptamine formulation (gh001) in healthy volunteers
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567880/
http://dx.doi.org/10.1192/j.eurpsy.2022.1846
work_keys_str_mv AT reckwegj aphase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT masonn aphase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT vanleeuwenc aphase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT tonness aphase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT terweyt aphase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT ramaekersj aphase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT reckwegj phase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT masonn phase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT vanleeuwenc phase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT tonness phase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT terweyt phase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers
AT ramaekersj phase1doserangingstudytoassesssafetyandpsychoactiveeffectsofavaporized5methoxynndimethyltryptamineformulationgh001inhealthyvolunteers